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Oxidative stressParaquat is a highly toxic herbicide that selectively accumulates in the lungs and causes pulmonary
damage through the oxidative and inflammatory processes. Carvedilol is a nonselective beta and
alpha-adrenergic blocking agent that has been shown to possess powerful antioxidant and anti-
inflammatory properties. In the present study, we evaluated the protective effects and the underlying
mechanisms of carvedilol on paraquat-induced lung injury in a mouse model. Mice were injected with
a single dose of paraquat (20 mg/kg, ip), and treated with carvedilol (10 and 20 mg/kg/day, orally) for
eight days. At the end of the experiment, lung tissue and blood samples were collected for histological
and biochemical analysis. The results showed that carvedilol treatment improved the histopathological
changes in the lung tissue of mice exposed to paraquat. Carvedilol significantly decreased the levels of
malondialdehyde (MDA), carbonyl protein, myeloperoxidase (MPO), and nitric oxide (NO), while
increased the levels of glutathione (GSH), superoxide dismutase (SOD), catalase and glutathione
reductase compared with paraquat group. Carvedilol treatment also significantly reduced the levels of
proinflammatory cytokines tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6, transforming growth
factor (TGF)-b1 and monocyte chemoattractant protein (MCP)-1 in the lung tissue. Treatment of mice
with carvedilol decreased paraquat-induced expression of nuclear factor kappa B (NF-jB). In addition
the plasma levels of matrix metalloproteinase (MMP)-9 and the lung hydroxyproline content
significantly reduced by carvedilol treatment. Taken together, these results indicate that carvedilol is able
to decrease the severity of paraquat-induced lung injury through inhibition of inflammation and
oxidative stress.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Paraquat (1,10-dimethyl-4,40-bipyridinium chloride) is one of
the most widely used herbicides and is highly toxic to animals
and humans. Because of its high toxicity, paraquat has been
banned in the European Union since 2007. However, it is a major
suicide agent in many countries. Paraquat poisoning causes dys-
function of multiple organs, mostly the lung. Paraquat selectively
accumulates in the lungs, resulting in pulmonary edema, hemor-
rhage, destruction of alveolar epithelial cells and ultimately fibro-
sis. The most common cause of death in acute paraquat poisoning
is pulmonary fibrosis and progressive respiratory failure [1].Oxidative stress and inflammation are two key mechanisms
suggested to be involved in the pathogenesis of paraquat-
induced lung injury. Paraquat undergoes redox cycling process
and generates a reactive oxygen species (ROS) and depletes cellular
NADPH. Reactive oxygen species are thought to be responsible for
the direct cell injury and induce intracellular transcription factors,
proinflammatory cytokines, inducible nitric oxide synthase (iNOS),
and cyclooxygenase (COX) all of which cause inflammation and
destruction of the lung tissue. It has also shown that paraquat
intoxication leads to activation and proliferation of fibroblasts
and deposition of collagen and other extracellular matrix proteins
in the alveolar walls. There is no effective therapy for paraquat poi-
soning, though several anti-inflammatory or antioxidant agents
have been investigated against paraquat induced lung injury [2,3].
Carvedilol is a nonselective beta and alpha-adrenergic blocking
agent clinically approved for the treatment of congestive heart fail-
ure and to reduce high blood pressure. Carvedilol has also been
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been suggested that the potent antioxidant properties of carvedilol
result from the tricyclic carbazole moiety in its structure. Carvedi-
lol exerts antioxidant properties independent of adrenoceptor
blockade. It was reported that the antioxidant activity of carvedilol
and its metabolites is much greater than that of vitamin E [4,5].
Several studies demonstrated that carvedilol is able to inhibit
proinflammatory and fibrogenic cytokines, leukocyte accumula-
tion, lipid peroxidation, and matrix metalloproteinases, all of
which promote tissue destruction and fibrosis [6,7]. The present
study was conducted to assess the possible protective effect of car-
vedilol against paraquat-induced lung injury in a mouse model. In
this study, we examined the changes in oxidative stress and
inflammatory markers and histopathological features in lung
tissues.2. Material and methods
2.1. Animal
Experiments were performed on Swiss albino mice weighing
25–30 g. Mice were kept in our animal house under controlled con-
ditions and allowed free access to tap water and a standard diet. All
animal procedures were performed in accordance with the
National Institute of Health’s Guide for the Care and Use of Labora-
tory Animals (NIH publication 85-23, revised 1996).
2.2. Experimental design
The animals were randomly divided into five groups (n = 8), as
follows: (1) control group, mice received saline solution. (2) car
group, mice received carvedilol (20 mg/kg/day, orally). (3) PQ
group, mice received paraquat (20 mg/kg, ip). (4) PQ + Car 10
group, mice received paraquat (20 mg/kg, ip) and carvedilol
(10 mg/kg/day, orally). (5) PQ + Car 20 group, mice received para-
quat (20 mg/kg, ip) and carvedilol (20 mg/kg/day, orally). Paraquat
was dissolved in saline solution and injected intraperitoneally in a
single toxic dose of 20 mg/kg of body weight. The dosage of para-
quat was based on our previous experiments [2]. Carvedilol was
suspended in 0.9% sodium chloride and administered by gavage
once daily for 8 consecutive days. Carvedilol was administered
one hour before the injection of paraquat. At the end of the exper-
iment, all animals from each group were anesthetized with keta-
mine and xylazine and their thoracic cavities were opened. Blood
was drawn from the heart, and the plasma fraction was collected
by centrifugation. Lung tissues were immediately removed and
washed in normal saline solution. Then, one part of each lung tis-
sue sample was fixed in formalin for histological examination, and
another part was frozen in liquid nitrogen and kept at 80 C until
analysis.
2.3. Preparation of lung tissue homogenate
Frozen tissue samples were homogenized in ice-cold Tris–HCl
buffer (pH 7.4, containing protease inhibitor cocktail) using a
homogenizer (Heidolph, Germany). All homogenized samples were
centrifuged at 20,000g for 20 min in a refrigerated centrifuge at
4 C. The supernatants were collected and stored at 80 C for bio-
chemical analysis.
2.4. Histopathological examination of lung tissue
The fixed tissue samples were embedded in paraffin and sec-
tions of 4 lm thickness were prepared and stained with hema-
toxylin and eosin (H&E). The slides were evaluated by an expertpathologist using a light microscope. The severity of lung damage
was scored according to the following histological parameters:
Alveolar wall thickness, the amount of cellular infiltration and
hemorrhage. The histological parameters were graded on a scale
of 0–3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).
2.5. Measurement of malondialdehyde (MDA)
The level of MDA in the lung tissues was determined using the
thiobarbituric acid (TBA) method [8]. Briefly, 100 ll of the super-
natant was added to a reaction mixture containing 100 ll of 20%
(w/v) trichloroacetic acid and 200 ll of TBA (0.1 M). The mixture
was incubated at 90 C for 60 min to complete the reaction. After
cooling, the samples were centrifuged at 10,000g for 5 min at
4 C and the supernatants were collected. The absorbance of the
supernatants was measured at 532 nm using a 96-well microplate
reader (BioTek, USA).
2.6. Measurement of carbonyl proteins
The levels of carbonyl proteins in the lung tissue were deter-
mined by a colorimetric method [9]. 50 ll of the sample was added
to 100 ll of 10 mM 2,4-dinitrophenylhydrazine (DNPH) in 2 M HCl
and incubated at room temperature for 1 h, with vortexing every
15 min. Then, 100 ll of 20% Trichloroacetic acid was added and
centrifuged at 15,000g for 5 min. The supernatant was discarded
and the pellet was washed with 1 ml ethanol-ethyl acetate (1:1
v/v) to remove excess DNPH. The final pellet was redissolved in
150 ll of 6 M guanidine hydrochloride in 20 mM potassium phos-
phate (pH 2.3). The absorbance was measured at 370 nm and car-
bonyl content was calculated using the molar extinction coefficient
of 22 mM1 cm1. The results were expressed as nmol carbonyl per
mg tissue.
2.7. Measurement of LDH
The plasma levels of lactate dehydrogenase (LDH) were mea-
sured using a commercial kit (Pars Azmun, Iran) and a spectropho-
tometer (Shimadzu UV-1800, Japan). The results were expressed as
units per liter (U/L).
2.8. Measurement of reduced glutathione (GSH)
To determine GSH, 50 ll of the supernatant was added to 50 ll
of 10% trichloroacetic acid. After shaking, the mixture was cen-
trifuged at 10,000g for 5 min at 4 C and the supernatant was sep-
arated from the pellet. An aliquot of the resulting supernatant
(50 ll) was added to 150 ll of phosphate buffer (0.2 M, pH 7.6,
1 mM EDTA) and 1 mM DTNB (5,50-Dithiobis-2-nitrobenzoic acid).
The absorbance of the yellow color was measured at 412 nm using
a microplate reader.
2.9. Measurement of superoxide dismutase (SOD) and glutathione
reductase (GR)
The activity of SOD and glutathione reductase enzymes in the
lung tissue was measured using a SOD assay kit (BioVision) and
Glutathione Reductase Assay Kit (Cayman Chemical) according to
the manufacturer’s protocol.
2.10. Measurement of catalase (CAT)
CAT activity was measured according to the method described
previously [10]. Briefly, a 10 lL aliquot of the supernatant was
added to a cuvette containing 0.5 ml of phosphate buffer
(50 mM, pH 7). The reaction was started by the addition of
Fig. 1. Effects of paraquat and carvedilol treatment on body weight changes in
mice. Carvedilol at a dose of 20 mg/kg/day attenuated paraquat-induced weight
loss in mice. Data are means ± SD. ⁄P < 0.01 compared with PQ group.
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was measured at 240 nm by using a spectrophotometer (Shimadzu
UV-1800, Japan). One unit of enzyme activity was defined as the
amount of enzyme decomposing 1 mM hydrogen peroxide per
minute.
2.11. Measurement of nitric oxide (NO)
The concentrations of nitrite and nitrate in the lung tissue were
evaluated as an index of NO production. Total levels of nitrate and
nitrite were measured using a Nitric Oxide Assay Kit (Enzo Life
Sciences). Results were expressed as nmol/mg tissue.
2.12. Measurement of myeloperoxidase (MPO)
The activity of MPO in the lung tissue was determined by mea-
suring the H2O2–dependent oxidation of tetramethylbenzidine
(TMB). Briefly, 50 ll of the sample was added to 50 ll of TMB solu-
tion (15 mM) and 100 lL of H2O2 (25 mM) diluted in phosphate
buffer (50 mM, pH 5.4). The assay was performed in a microplate
and the rate of change in absorbance was measured at 370 nm
using a microplate reader. One unit of MPO activity was defined
as the quantity of enzyme degrading 1 lmol of H2O2 per min at
25 C. The results were expressed as mU MPO/mg tissue
2.13. Measurement of pro-inflammatory cytokines
The levels of cytokines TNF-a, IL-1b, IL-6, TGF-b1 and chemo-
kine MCP-1 in the lung tissue were measured by using mouse
ELISA kits from eBioscience according to the manufacturer’s
instructions.
2.14. RT-PCR analysis of NF-jB in lung tissue
Total RNA was extracted from lung tissue samples using TRIzol
Reagent (Roche) and treated with DNase I. Synthesis of the cDNA
was performed using a First Strand cDNA Synthesis Kit (Thermo
Scientific, USA) according to the manufacturer’s instructions. The
mRNA expression level of NF-jB was measured by semi-
quantitative RT-PCR. The sequences of primers were as follows:
NF-jB forward, ACCTTTGCTGGAAACACACC and reverse,
ATGGCCTCGGAAGTTTCTTT; GAPDH forward, CAAGGTCATCCATGA-
CAACTTTG and reverse, GTCCACCACCCTGTTGCTGTAG.
2.15. Measurement of Hydroxyproline
The concentration of hydroxyproline in the lung tissue was
measured according to the method described in our previous study
[2]. Briefly, all samples were hydrolyzed in 6 N HCl for 12 h at
120 C. 50 ll of the samples were added to a 96-well plate and kept
at 60 C until the HCl was completely evaporated. Hydroxyproline
oxidation was initiated by addition of 100 ll of chloramine T
reagent (0.05 M). After shaking, the plate was incubated for
20 min at room temperature. To develop the color 100 ll of
p-dimethylaminobenzaldehyde solution (1 M) was added to each
well and the plate was incubated for 20 min at 60 C. After cooling,
the absorbance was read at 570 nm using a microplate reader. The
hydroxyproline concentrations were calculated using a standard
curve of known concentrations of hydroxyproline. The results were
expressed as microgram of hydroxyproline per mg tissue.
2.16. Measurement of MMP-9
The plasma levels of matrix metalloproteinase-9 (MMP-9) were
measured using an ELISA kit (Mouse Total MMP-9 QuantikineELISA Kit, R&D Systems) according to the manufacturer’s
instructions.
2.17. Statistical analysis
Data were expressed as mean ± SD. Statistical comparisons
were performed using one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s test. P < 0.05 was considered significant.
3. Results
3.1. Effects of carvedilol and paraquat on body weight
We examined the body weight of the mice from day 1 to day 8.
Administration of paraquat (20 mg/kg, ip, single dose) caused a sig-
nificant weight loss in mice as compared to the control group
(Fig. 1). During the whole experimental period, body weight loss
was significantly attenuated in the mice treated with PQ + carvedi-
lol (20 mg/kg/day) as compared to that in the PQ group. Carvedilol
treatment at dose of 10 mg/kg/day also slightly increased the body
weight of mice but the difference between this group and the PQ
group was not significant (except the second day).
The difference of body weight between the control and
carvedilol-only treated group was not significant over the whole
experimental period.
3.2. Effects of carvedilol and paraquat on the ratio of lung weight to
body weight (LW/BW)
At the end of the experiment, pulmonary edema was evaluated
using the ratio of wet lung weight to body weight. Paraquat admin-
istration caused an increase in the ratio of LW/BW, however treat-
ment with carvedilol (20 mg/kg/day) significantly decreased the
LW/BW ratio (P = 0.016) (Fig. 2). No significant change in the LW/
BW ratio was observed in PQ + low dose carvedilol (10 mg/kg/day)
compared with PQ group (P = 0.056).
3.3. Effects of carvedilol against paraquat-induced pathological
changes
Histopathological changes caused by paraquat and carvedilol
treatment in the lung tissues of mice were assessed by H&E stain-
ing (Fig. 3A). Paraquat administration induced a significant inflam-
matory response characterized by widespread inflammatory cell
infiltration in the alveolar space and septum, thickening of the
Fig. 2. Effects of paraquat and carvedilol treatment on the ratio of lung weight to
body weight (LW/BW). The ratio of LW/BW was determined at the end of the study,
on day 8. Carvedilol at the dose of 20 mg/kg/day decreased paraquat-induced
increase in the ratio of LW/BW in mice. Data are means ± SD. #P < 0.001 compared
with control group; ⁄P < 0.05 compared with PQ group.
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histopathological changes were markedly improved by the
treatment with carvedilol at the dose of 20 mg/kg/day. NoFig. 3. (A) Histopathological appearance of lung tissues in (a) normal control, (b) carved
kg/day) groups. Widespread thickening of alveolar septum, infiltration of inflammatory c
the histopathological alterations induced by paraquat. The lung tissue sections were anal
score of lung tissue in each group. Histopathology score of lung was significantly lower
presented as the mean of the total score ± SD. #P < 0.001 compared with control group;histopathological alteration was observed in the lung of carvedilol
only-treated mice. As shown in Fig. 3B, the total histopathological
score was significantly elevated in the paraquat treated mice
compared with the control mice (P < 0.001). Treatment with carve-
dilol (20 mg/kg/day) showed a significant decrease (P = 0.016) in
the histopathological score when compared with the PQ group.
However, the histopathological score was not significantly lower
in the mice treated with the low dose of carvedilol (10 mg/kg/day)
as compared to the PQ group.3.4. Effects of carvedilol and paraquat on the levels of MDA, protein
carbonyl and LDH
Oxidative stress induced by paraquat was examined by measur-
ing the level of MDA, a marker of lipid peroxidation, and protein
carbonyl content as a marker of protein oxidation (Table 1). The
results showed that paraquat administration significantly
increased the level of MDA and protein carbonyl content in the
lung tissue. Treatment with carvedilol (20 mg/kg/day) significantly
prevented paraquat induced increase of MDA and protein carbonyl
formation (P < 0.01). Treatment of mice with the low dose of carve-
dilol (10 mg/kg/day) also significantly decreased the levels of pro-
tein carbonyl (P < 0.01). Furthermore, in the present study the
plasma levels of LDH as a marker of cell membrane damage were
measured (Table 1). The plasma levels of LDH in mice treated with
paraquat were significantly increased in comparison to normalilol only (c) PQ, (d) PQ + carvedilol (10 mg/kg/day) and (e) PQ + carvedilol (20 mg/
ells, and hemorrhage were observed in PQ group. Treatment with carvedilol reduced
yzed by H&E staining (magnification is 400 and 600). (B) Total histopathological
in the PQ + carvedilol (20 mg/kg/day) group than in the PQ group. The results are
⁄P < 0.05 compared with PQ group.
Table 1
Effects of carvedilol on the levels of MDA, protein carbonyl and LDH in each group.
Groups MDA
(nM/mg tissue)
Protein carbonyl
(nM/mg tissue)
LDH
(U/L plasma)
Control 8.8 ± 5.16 0.26 ± 0.07 138.9 ± 51.3
Carvedilol 9.57 ± 5.6 0.26 ± 0.04 119.7 ± 73.4
PQ 39.9 ± 5.6# 1.17 ± 0.31# 322.3 ± 73.7#
PQ + Carvedilol (10) 32.9 ± 9.8 0.71 ± 0.13** 275.6 ± 65.8
PQ + Carvedilol (20) 19.46 ± 12** 0.5 ± 0.29** 189.2 ± 71.1*
Data are means ± SD.
# P < 0.01 compared with control group.
* P < 0.05.
** P < 0.01 compared with PQ group.
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cantly reduced paraquat induced increase of LDH (P = 0.02).
3.5. Effects of carvedilol and paraquat on the levels of GSH, SOD, CAT
and GR
Sustained oxidative stress caused by paraquat leads to the
depletion of GSH along with the antioxidant enzymes SOD, CAT
and GR in the lung tissue when compared with those in the control
group (Fig. 4A–D). Treatment with carvedilol (20 mg/kg/day), sig-
nificantly restored the levels of GSH (P < 0.001), SOD (P = 0.032),
CAT (P = 0.014) and GR (P = 0.032) activity in the lung tissue as
compared with those in the PQ group. The level of GSH was also
significantly increased at the low dose of carvedilol (10 mg/kg/day,
p < 0.01).Fig. 4. Effect of carvedilol treatment on paraquat-induced changes in the levels of (A) GS
with control group; ⁄P < 0.05, ⁄⁄P < 0.001 compared with PQ group.3.6. Effects of carvedilol and paraquat on the levels of MPO and NO
A single injection of paraquat caused significant elevation in
lung tissue levels of MPO and NO as compared to the control group
(Fig. 5A and B). Treatment with carvedilol (20 mg/kg/day), signifi-
cantly reduced the activity of MPO (P = 0.033) and the levels of
NO (P < 0.001) in lung tissue as compared to those in the PQ group.3.7. Effects of carvedilol and paraquat on the levels of pro-
inflammatory cytokines
The levels of proinflammatory cytokines TNF-a, IL-1b, IL-6, TGF-
b1 and chemokine MCP-1 in the lung tissue were significantly ele-
vated in the paraquat treated group as compared to the normal
control group (P < 0.001) (Fig. 6A–E). Treatment of mice with car-
vedilol (20 mg/kg/day) significantly decreased the production of
TNF-a (P = 0.024), IL-1b (P = 0.004), IL-6 (P = 0.001), TGF-b1
(P < 0.001) and MCP-1(P = 0.001) in the lung tissue as compared
to the mice treated with paraquat. Treatment of mice with the
low dose of carvedilol (10 mg/kg/day) also significantly decreased
the levels of IL-6 (P = 0.027) and TGF-b1 (P < 0.001).3.8. Effects of carvedilol and paraquat on the mRNA expression level of
NF-kB
As shown in Fig. 7, the mRNA expression level of NF-jB in the
lungs of mice treated with paraquat significantly increased when
compared with control mice (P < 0.01). Treatment with carvedilolH, (B) SOD, (C) CAT and (D) GR. Data are means ± SD. §P < 0.01, #P < 0.001 compared
Fig. 5. Effects of carvedilol and paraquat on the levels of (A) MPO and (B) NO in the
lung tissue. Treatment with carvedilol (20 mg/kg/day) remarkably reduced the
levels of MPO and NO in the lung tissue compared with the PQ group. Data are
means ± SD. §P < 0.01, #P < 0.001 compared with control group; ⁄P < 0.05, ⁄⁄P < 0.001
compared with PQ group.
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in the lungs of mice exposed to paraquat (P < 0.01).
3.9. Effects of carvedilol and paraquat on the hydroxyproline content
Lung fibrosis was assessed by the collagen deposition in the
lung tissue. Hydroxyproline is the main component of collagen
protein and we measured the hydroxyproline content as a marker
of fibrosis in the lung tissue (Fig. 8). The lung hydroxyproline con-
tent was significantly increased in mice treated with paraquat
compared to normal control mice. However treatment with carve-
dilol at both doses (10 and 20 mg/kg/day) significantly reduced the
lung hydroxyproline content (p = 0.025 and P < 0.001).
3.10. Effects of carvedilol and paraquat on the levels of MMP-9
Wemeasured total plasma levels of MMP-9 in order to evaluate
lung inflammation and fibrosis induced by paraquat. As shown in
Fig. 9, Paraquat exposure significantly increased the plasma levels
of MMP-9 compared to control group (P < 0.001). The levels of
MMP-9 were significantly reduced at both doses of carvedilol (10
and 20 mg/kg/day, P < 0.001).4. Discussion
Lung injury is the most serious and fatal complication of para-
quat poisoning. The present study revealed that carvedilol treat-
ment ameliorated the severity of paraquat-induced lung injury.
To study the possible mechanisms responsible for the protective
effect of carvedilol on paraquat-induced lung injury, we deter-
mined the oxidative and inflammatory biomarkers in lung tissue.
Previous studies showed that oxidative stress plays an impor-
tant role in the development and progression of paraquat-
induced lung damage. Paraquat is reduced intracellularly by an
NADPH-dependent reaction to paraquat radical and oxidized back
to paraquat cation in the presence of oxygen. These reactions lead
to production of the highly toxic molecules such as superoxide
anion (O2), hydrogen peroxide (H2O2), hydroxyl free radical
(HO) and peroxynitrite (ONOO) in the mitochondria and cytosol
of cells. Oxygen radicals are highly reactive to cellular macro-
molecules and cause direct oxidative damage to proteins, mem-
brane lipids and nucleic acids, which may lead to cell death
[11,12]. Free radicals can abstract hydrogen atoms from polyunsat-
urated fatty acids in cell membranes and lipoproteins, causing lipid
peroxidation. Oxidation of lipids is considered as an important step
in the mechanism of paraquat toxicity in mammalian cells [1].
Reaction of oxygen radicals with unsaturated lipids produces sec-
ondary oxidation products such as 4-hydroxynonenal and malon-
dialdehyde (MDA) which has been commonly used as a
convenient biomarker of lipid peroxidation process [13]. Intracel-
lular paraquat redox cycling can cause oxidation of amino acids
in proteins and lead to the formation of protein carbonyl deriva-
tives. Increased protein carbonylation, as an important biomarker
of oxidative stress, has been reported in paraquat induced cytotox-
icity [14]. In agreement with other studies, our results showed that
paraquat significantly increasedMDA level as a marker of lipid per-
oxidation and carbonylation of proteins in the lung tissue. Treat-
ment with carvedilol significantly prevented lipid peroxidation
and protein carbonylation process induced by paraquat. It has been
shown that carvedilol is extremely lipophilic and concentrates in
lipid membranes and able to protect cell membranes from lipid
peroxidation [5]. It has also been demonstrated that administra-
tion of carvedilol decreased protein carbonylation as a marker of
cellular protein injury [15]. The ability of carvedilol to prevent oxi-
dation of cellular lipids and proteins indicates that carvedilol treat-
ment improves the antioxidant status in the lung tissue of mice
exposed to paraquat.
In the present study the plasma levels of LDH as a marker of cell
membrane damage were measured. Plasma levels of this intracel-
lular enzyme may also be used to indicate the extent of cell mem-
brane oxidative damage induced by paraquat. Administration of
paraquat increased the levels of LDH however treatment with car-
vedilol reduced the elevation of plasma LDH. This finding is in cor-
relation with histopathological findings and may indicate the
protective effect of carvedilol against paraquat induced lung tissue
damage.
The cells have endogenous antioxidant defense systems which
protect cells against oxygen free radical damage. Reduced glu-
tathione (GSH) as thiol-containing peptide is the major endoge-
nous antioxidant produced by the cells and plays an important
role in intracellular protection against reactive oxygen species.
During oxidative stress, GSH is converted to its oxidized form, glu-
tathione disulfide (GSSG). GSH is regenerated from GSSG by the
enzyme glutathione reductase, using NADPH as an electron donor.
It is also involved in a variety of cellular functions such as DNA
repair mechanisms and nonenzymatic conjugation with some
chemicals to detoxify them [12,16]. The main antioxidant enzymes
involved in the elimination of reactive oxygen species include
Fig. 6. Effects of carvedilol and paraquat on (A) TNF-a, (B) IL-1b, (C) IL-6, (D) TGF-b1 and (E) MCP-1 production in lung tissue of mice. Administration of paraquat increased
the levels of TNF-a, IL-1b, IL-6, TGF-b1 and MCP-1 in the lung tissue, whereas treatment with carvedilol (20 mg/kg/day) prevented the paraquat-induced increase in TNF-a, IL-
1b, IL-6, TGF-b1 and MCP-1. Data are means ± SD. #P < 0.001 compared with control group; ⁄P < 0.05, ⁄⁄P < 0.01 compared with PQ group.
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SOD is a metalloenzyme, which catalyzes the dismutation of super-
oxide anions into hydrogen peroxide and molecular oxygen.
Hydrogen peroxide is a highly reactive oxidizing agent and can
be broken down into water and oxygen by the enzyme catalase
[17]. In the present study we showed that paraquat-induced lung
injury is associated with a significant decrease in SOD, catalase
and glutathione reductase enzymes and GSH content of the lung
tissue. Depletion of GSH in mice treated with paraquat can be
caused by GSH consumption due to the interaction of GSH with
reactive oxygen species and toxic products. Reduction of GSHresults in accumulation of toxic radicals and enhancement of lipid
peroxidation in the lung tissue. We also suggest that, the reduction
in SOD, catalase and glutathione reductase enzymes activity can be
attributed to the enzyme consumption because of neutralization of
excessive superoxide anions and hydrogen peroxide in the lung tis-
sue. It has been reported that pre-treatment with glutathione
reductase has a protective effect against harmful paraquat poison-
ing, probably due to glutathione recycling [16]. Carvedilol treat-
ment inhibited the depletion of GSH and restored SOD, catalase
and glutathione reductase activity in the lung tissue of mice
exposed to paraquat. The ability to increase the levels of
Fig. 7. Effect of carvedilol treatment on paraquat-induced changes in NF-jB mRNA
expression in lung tissue. The mRNA levels were normalized by the expression of
GAPDH. Data are means ± SD of three experiments. #P < 0.01 compared with control
group; ⁄P < 0.01 compared with PQ group.
Fig. 8. The lung hydroxyproline content in each group. Paraquat administration
increased hydroxyproline levels and treatment with carvedilol inhibited the
increase of lung hydroxyproline content. Data are means ± SD. #P < 0.001 compared
with control group; ⁄P < 0.05, ⁄⁄P < 0.001 compared with PQ group.
Fig. 9. Effects of carvedilol treatment on paraquat-induced changes in the plasma
levels of MMP-9. Treatment with carvedilol inhibited the paraquat-induced
increase in MMP-9 levels. Data are means ± SD. #P < 0.001 compared with control
group; ⁄P < 0.01, ⁄⁄P < 0.001 compared with PQ group.
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carvedilol and may be one of the mechanisms of action of carvedi-
lol in paraquat-induced lung injury. Therefore, in the present study
we showed that carvedilol treatment altered the oxidant-
antioxidant balance in favor of antioxidants and improved lung
damage induced by paraquat.
Nitric oxide (NO) has been suggested as another important
mediator of paraquat toxicity, even though its role in the patho-
genesis of paraquat induced lung injury has been controversial. It
has been shown that paraquat may induce nitric oxide synthase
(NOS), the enzyme producing NO from L-arginine, through various
mechanisms, such as activation of nuclear factor kappa B (NF-jB),
proinflammatory cytokines and reactive molecules. NO as a free
radical easily reacts with superoxide anion (O2) derived from the
redox cycling of paraquat, to form peroxynitrite (ONOO). Perox-
ynitrite is a highly toxic oxidant that causes oxidation of proteins,
lipids and nucleic acids leading to tissue damage in a process
known as nitrosative stress [18,19]. In the present study, our find-
ings showed that paraquat exposure results in an increase in the
levels of NO in the lung tissue. Carvedilol administration signifi-
cantly decreased the excessive production of NO in the lung tissue
of mice treated with paraquat. This finding suggests that carvedilol
may prevent paraquat induced lung damage by inhibiting NO-
mediated cytotoxicity.
It has been demonstrated that inflammatory response induced
by paraquat is involved in the development of pulmonary injury.
During inflammation of the lung, activated neutrophils migrate
from pulmonary vasculature into the interstitial and alveolar
spaces, where they release proinflammatory mediators and reac-
tive oxygen radicals [20]. In the present study we showed that
the activity of myeloperoxidase (MPO) as a biochemical marker
of neutrophil infiltration was significantly increased in the lung tis-
sue of mice treated with paraquat. MPO is a peroxidase enzyme
found in the azurophilic granules of neutrophils and is released fol-
lowing neutrophil activation by inflammatory stimuli. MPO cat-
alyzes the formation of hypochlorous acid (HOCl), a potent
oxidative agent, from chloride and hydrogen peroxide and con-
tributes to tissue damage during oxidative stress and inflamma-
tion. Administration of carvedilol caused a significant reduction
of the inflammatory cell infiltration and MPO activity in the lung
tissue of mice receiving paraquat. In agreement with this finding,
it has been reported that carvedilol is able to reduce MPO activity
in inflammatory disorders [7,21]. The protective effect of carvedilol
against paraquat-induced pulmonary injury may be partially
described by the ability of this drug to reduce neutrophil infiltra-
tion into the lungs. Consistent with these findings, our histological
analysis showed that paraquat induced a significant infiltration of
inflammatory cells, thickening of the alveolar septum and hemor-
rhage, while treatment with carvedilol reduced the histological
changes and pathologic score in the lung tissues.
Previous studies showed that several cytokines, chemokines,
and fibrogenic mediators play an important role in the molecular
mechanisms of pulmonary inflammation and fibrosis induced by
paraquat. Inflammatory cells secrete a variety of proinflammatory
cytokines such as TNF-a, IL-1b, IL-6, TGF-b1 and chemokine MCP-1,
which intensify inflammatory reactions and lead to lung injury
[2,22]. TNF-a is one of the first cytokines produced by alveolar
macrophages and has the ability to promote alveolar epithelial
dysfunction in paraquat induced lung injury. TNF-a triggers the
production of other inflammatory cytokines and chemokines and
induces infiltration of neutrophils which exacerbate lung tissue
damage. It has also been shown that TNF-a can trigger multiple
signaling pathways involved in chronic inflammation and plays a
major role in the development of fibrosis in various organs such
as liver, kidney and lung [23,24]. IL-1b and IL-6 are potent and
pleiotropic cytokines thought to be involved in lung inflammation
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paraquat-induced lung injury and promotes fibrogenesis either
alone or in combination with TNF-a [24]. It has been shown that
IL-1b is a potent inducer of TGF-b, and at least a part of the profi-
brotic effects of IL-1b is mediated by this growth factor [25]. Trans-
forming growth factor (TGF)-b1 is secreted by numerous cell types
including fibroblasts and macrophages. It is an important regulator
of cell growth and differentiation and identified as the most impor-
tant pro-fibrotic cytokine. TGF-b1 has been implicated as a media-
tor of chronic inflammation and fibrosis in many tissues including
the lung. TGF-b1 stimulates the proliferation and differentiation of
alveolar epithelial cells and fibroblasts as well as production of
matrix metalloproteinases and collagen [26,27]. The monocyte
chemoattractant protein (MCP)-1 is a member of the C-C chemo-
kine family and regulates migration and infiltration of monocytes/
macrophages. MCP-1 is produced by several cells such as
endothelial cells, alveolar epithelial cells and macrophages. This
proinflammatory protein is implicated in the pathogeneses of
various inflammatory diseases. It has been reported that MCP-1
plays an important role in the development of lung inflammation
and fibrosis [28,29]. In agreement with previous studies, we also
found that the administration of paraquat caused a significant
increase in the levels of proinflammatory cytokines TNF-a, IL-1b,
IL-6, TGF-b1 and chemokine MCP-1 in the lung tissue. As
mentioned above, these mediators have an important role in the
progression of paraquat induced lung inflammation and fibrosis.
Treatment with carvedilol significantly decreased the levels of
these proinflammatory mediators and eventually attenuated lung
damage. It should be noted that the anti-inflammatory effects of
carvedilol have been reported in various experimental models. It
has been demonstrated that carvedilol reduced cardiac gene
expression and production of TNF-a, IL-6, IL-1b and TGF-b1
in acute myocardial infarction and azithromycin-induced
cardiotoxicity [6,30]. It has also been shown that the administra-
tion of carvedilol is able to significantly reduce the expression
and activity of MCP-1 as well as macrophage infiltration in
myocardial tissue [31].
Several studies have demonstrated that free radicals are
involved in modulating the activation of NF-jB signaling pathway
in paraquat-induced lung injury [32,33]. NF-jB is an important
transcription factor that regulates cellular responses to reactive
oxygen species and inflammatory mediators. NF-jB induces tran-
scription of proinflammatory and fibrogenic cytokines TNF-a, IL-
1b, IL-6, TGF-b1 and chemokine MCP-1 and several other adhesion
molecules. Upregulation of redox-sensitive transcription factor NF-
jB has also been shown to induce inflammatory target protein
MMP-9, which contributes to pulmonary inflammation and fibrosis
[34]. It has been shown that paraquat-induced activation of NF-jB
may induce the expression of inducible form of NOS, which cat-
alyzes the formation of NO [19,35]. As we mentioned above, NO
has been suggested as an important mediator of paraquat toxicity.
In the present study, we demonstrated that paraquat exposure
induced NF-jB activity and treatment with carvedilol significantly
reduced paraquat-induced NF-jB activation in the lung tissue.
Indeed, carvedilol shows an inhibitory effect on the activation of
redox-sensitive transcription factor NF-jB, which may be related
to its potent antioxidant properties.
Consistent with previous studies, we showed that lung hydrox-
yproline content as a marker of fibrosis was significantly elevated
in mice treated with paraquat, and treatment with carvedilol
reduced the hydroxyproline content in the lung tissue of mice
exposed to paraquat. Administration of carvedilol has been
reported to inhibit the formation of hydroxyproline in an experi-
mental model of liver injury and myocardial infarction [36,37].
Various studies suggested that the activation of matrix metallopro-
teinases (MMPs) is involved in pulmonary fibrosis by differentsignal transduction pathways. MMP-9 is one of the most important
pro-fibrotic members of the metalloproteinase family, and it has
been suggested that MMP-9 plays an important role in paraquat
induced lung inflammation and fibrosis. In the lung tissue, MMP-
9 is produced by inflammatory and airway epithelial cells under
the influence of proinflammatory cytokines such as TNF-a, IL-1b
and TGF-b, and other toxic molecules such as reactive oxygen spe-
cies [34,38,39]. In the present study, the plasma levels of MMP-9,
as a marker of pulmonary inflammation and fibrosis, were
increased in mice treated with paraquat, while treatment with car-
vedilol significantly inhibited the increase of MMP-9 levels. This
observation is supported by previous studies demonstrating that
carvedilol reduces the expression and activity of MMP-9 in
patients with heart failure and experimental models of atheroscle-
rosis and periodontitis [7,40,41].
In conclusion, the current study is the first to suggest that car-
vedilol may attenuate the paraquat-induced lung injury through
antioxidant and anti-inflammatory mechanisms. Further studies
are needed to determine whether carvedilol could be used to pro-
tect against paraquat-induced lung toxicity in humans.References
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